文献速递肝病

肝硬化患者的止血改变与止血管理

Haemostatic alterations and management of haemostasis in patients with cirrhosis.
PubMed 文献 · J Hepatol · 2022-01-01

肝硬化患者常出现血小板计数下降及多种止血蛋白水平降低等复杂止血系统改变。目前广泛认为,由于促止血与抗止血系统同时发生变化,肝硬化患者的止血系统仍处于平衡状态。这种「再平衡」概念已改变临床管理,但缺乏设计良好的临床研究提供确凿证据。本文概述肝硬化患者出血与血栓并发症的发病机制、预防和治疗进展。

要点

  • 肝硬化患者止血系统因促止血与抗止血系统同时改变而处于再平衡状态。
  • 许多凝血酶原时间延长的肝硬化患者行侵入性操作时已不再预防性使用新鲜冰冻血浆。
  • 临床医生已更加意识到肝硬化患者需要抗血栓治疗,即使常规凝血试验异常。

核心结论

  • 肝硬化患者的止血系统因促止血与抗止血系统同时改变而处于再平衡状态,这一概念已改变临床管理,但设计良好的临床研究证据仍 largely 缺乏。

研究设计与样本

  • 本文为综述,概述肝硬化患者出血与血栓并发症的发病机制、预防和治疗进展。

主要发现

  • 肝硬化患者常出现血小板计数下降和多种止血蛋白水平降低等复杂止血系统改变。
  • 历史上肝硬化患者被认为有止血相关出血倾向,现广泛认为其止血系统因促止血与抗止血系统同时改变而保持平衡。
  • 许多凝血酶原时间延长的肝硬化患者行侵入性操作时已不再预防性使用新鲜冰冻血浆。
  • 临床医生已更加意识到肝硬化患者需要抗血栓治疗,即使常规凝血试验异常。

临床怎么用

  • 许多凝血酶原时间延长的肝硬化患者行侵入性操作时已不再预防性使用新鲜冰冻血浆。
  • 临床医生已更加意识到肝硬化患者需要抗血栓治疗,即使常规凝血试验异常。

局限性

  • 原文指出,设计良好的临床研究提供的确凿证据仍 largely 缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with cirrhosis frequently acquire complex changes in their haemostatic system including a decreased platelet count and decreased levels of various haemostatic proteins. Although historically patients with cirrhosis were thought to have a haemostasis-related bleeding tendency, it is now widely accepted that the haemostatic system of patients with cirrhosis remains in balance as a result of simultaneous changes in pro- and anti-haemostatic systems. The concept of rebalanced haemostasis has led to changes in clinical management, although firm evidence from well-designed clinical studies is largely lacking. For example, many invasive procedures in patients with cirrhosis and a prolonged prothrombin time are now performed without prophylaxis with fresh frozen plasma. Conversely, clinicians have become more aware of the need for anti-thrombotic therapy, even in those patients with abnormal routine coagulation tests. This paper will outline recent advances in pathogenesis, prevention and treatment of both bleeding and thrombotic complications in patients with cirrhosis. Among other topics, we will discuss the haemostatic status of acutely ill patients with cirrhosis, the various causes of bleeding in patients with cirrhosis, and how best to prevent or treat bleeding. In addition, we will discuss the hypercoagulable features of patients with cirrhosis, new insights into the pathogenesis of portal vein thrombosis, and how best to prevent or treat thromboses.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lisman T, Caldwell SH, Intagliata NM, et al. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol. 2022. PMID: 35589251. doi:10.1016/j.jhep.2021.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。